Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
作者信息
Riggs J E
出版信息
Clin Neuropharmacol. 1982;5(3):277-92. doi: 10.1097/00002826-198205030-00003.
Abstract
摘要
相似文献
1
Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
Clin Neuropharmacol. 1982;5(3):277-92. doi: 10.1097/00002826-198205030-00003.
2
[Therapy of myasthenia gravis in pregnancy].
Minerva Ginecol. 1980 Jan-Feb;32(1-2):21-6.
3
Treatment of myasthenia gravis.
N Engl J Med. 1973 Jan 4;288(1):27-31. doi: 10.1056/NEJM197301042880107.
4
[Myasthenia gravis pseudoparalytica. Clinical picture, pathogenesis, therapy].
Med Klin. 1973 Jun 1;68(22):723-30.
5
[On the treatment of myasthenia].
Rev Med Liege. 1968 Sep 15;23(18):552-7.
6
The interaction of human cholinesterases with anticholinesterases used in the therapy of myasthenia gravis.
Ann N Y Acad Sci. 1966 Jan 26;135(1):287-301. doi: 10.1111/j.1749-6632.1966.tb45477.x.
7
[Current treatment of myasthenia gravis].
Rev Paul Med. 1965 Oct;67(4):231-42.
8
Treatment of myasthenia--I.
Br Med J. 1971 Apr 17;2(5754):160-2.
9
[Current therapy of myasthenia gravis. I. Specific symptomatic therapy].
Nervenarzt. 1972 Jul;43(7):341-4.
10
Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Eur Arch Psychiatry Neurol Sci. 1985;234(6):374-7. doi: 10.1007/BF00386054.
Zotero 插件